Monday, May 27, 2013
While the equity markets have
clear appetite for new biotech paper, the oversubscribed Athyrium Opportunities
Fund L.P. shows investors are not turning a blind eye to alternative financing
Athyrium Capital Management and partner Neuberger Berman closed the
life sciences credit fund at $507 million last week. The size is well above the
original target of $350 million.